Manufacturer of Idrasil™, the first standardized medical cannabis, launches after 14 years of research and development, takes aim at U.S. pharmaceutical industry and its opioid epidemic.
ANAHEIM, Calif., Sept. 17, 2024 /PRNewswire/ — C3 Pharmaceuticals, Inc., a private biopharmaceutical company formed to leverage first-mover advantage and play a leadership role in the emerging pharmaceutical cannabinoid therapeutics health sector, is pleased to announce that it executed a tailored Share Subscription Agreement (SSA) with GEM Global Yield LLC SCS (“GGY“) and is planning on listing on the Canadian Securities Exchange. The listing will offer investors the solution to the cannabis prescribing problem in America, which originated from a misunderstood prohibition in the 1940s.
Idrasil, the primary intellectual property held by C3 Pharmaceuticals, Inc., is a dry, anhydrous, scored tablet containing a standardized and consistent amount…
